Patterns of improved survival in patients with multiple myeloma in the twenty-first century: a population-based study
- PMID: 20038719
- PMCID: PMC2834396
- DOI: 10.1200/JCO.2009.25.4177
Patterns of improved survival in patients with multiple myeloma in the twenty-first century: a population-based study
Abstract
PURPOSE Randomized multiple myeloma (MM) studies show improved response rates and better progression-free survival for newer therapies. However, a less pronounced effect has been found for overall survival (OS). Using population-based data including detailed treatment information for individual patients, we assessed survival patterns for all patients diagnosed with MM in Malmö, Sweden from 1950 to 2005. PATIENTS AND METHODS We identified 773 patients with MM (48% males). On the basis of the age limit used for treatment with high-dose melphalan with autologous stem-cell support (HDM-ASCT; < or = 65 years old) in Sweden, we constructed Kaplan-Meier curves and used the Breslow generalized Wilcoxon test to evaluate OS patterns (diagnosed in six calendar periods) for patients 65 years old or younger and patients older than 65 years. Results Including all age groups, patients diagnosed from 1960 to 1969 had a better survival than patients diagnosed from 1950 to 1959. In subsequent 10-year calendar periods, median OS increased from 24.3 to 56.3 months (P = .036) in patients < or = 65 years old. In contrast, OS did not improve among patients older than age 65 years (21.2 to 26.7 months, P = .7). CONCLUSION With the establishment of HDM-ASCT as the standard therapy for younger patients with MM, OS has improved significantly for this age group in the general MM population. With novel therapies being commonly used at disease progression, presumably it becomes increasingly difficult to confirm survival differences between defined induction, consolidation, and maintenance therapies in the future. Consequently, in the era of novel MM therapies, population-based studies will serve as a necessary complement to randomized trials.
Conflict of interest statement
Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.
Figures

Similar articles
-
Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.Lancet Oncol. 2015 Dec;16(16):1617-29. doi: 10.1016/S1470-2045(15)00389-7. Epub 2015 Nov 17. Lancet Oncol. 2015. PMID: 26596670 Clinical Trial.
-
Autologous stem cell transplantation in first remission is associated with better progression-free survival in multiple myeloma.Ann Hematol. 2018 Oct;97(10):1869-1877. doi: 10.1007/s00277-018-3370-1. Epub 2018 May 21. Ann Hematol. 2018. PMID: 29781040
-
Autologous transplantation and maintenance therapy in multiple myeloma.N Engl J Med. 2014 Sep 4;371(10):895-905. doi: 10.1056/NEJMoa1402888. N Engl J Med. 2014. PMID: 25184862 Clinical Trial.
-
Shifts in the therapeutic paradigm for patients newly diagnosed with multiple myeloma: maintenance therapy and overall survival.Clin Cancer Res. 2011 Mar 15;17(6):1253-63. doi: 10.1158/1078-0432.CCR-10-1925. Clin Cancer Res. 2011. PMID: 21411441 Review.
-
Augmenting Autologous Stem Cell Transplantation to Improve Outcomes in Myeloma.Biol Blood Marrow Transplant. 2016 Nov;22(11):1926-1937. doi: 10.1016/j.bbmt.2016.06.004. Epub 2016 Jun 8. Biol Blood Marrow Transplant. 2016. PMID: 27288955 Review.
Cited by
-
Identifying Educational Needs and Practice Gaps of European Hematologists and Hematology Nurses in the Treatment and Management of Multiple Myeloma.Hemasphere. 2018 Mar 1;2(2):e33. doi: 10.1097/HS9.0000000000000033. eCollection 2018 Mar-Apr. Hemasphere. 2018. PMID: 31723761 Free PMC article.
-
Racial disparities in incidence and outcome in multiple myeloma: a population-based study.Blood. 2010 Dec 16;116(25):5501-6. doi: 10.1182/blood-2010-07-298760. Epub 2010 Sep 7. Blood. 2010. PMID: 20823456 Free PMC article.
-
Trends in autologous hematopoietic cell transplantation for multiple myeloma in Europe: increased use and improved outcomes in elderly patients in recent years.Bone Marrow Transplant. 2015 Feb;50(2):209-15. doi: 10.1038/bmt.2014.255. Epub 2014 Nov 10. Bone Marrow Transplant. 2015. PMID: 25387088 Clinical Trial.
-
Trends of survival in patients with multiple myeloma in Japan: a multicenter retrospective collaborative study of the Japanese Society of Myeloma.Blood Cancer J. 2015 Sep 18;5(9):e349. doi: 10.1038/bcj.2015.79. Blood Cancer J. 2015. PMID: 26383822 Free PMC article. No abstract available.
-
Prognostic nomogram for multiple myeloma early relapse after autologous stem cell transplant in the novel agent era.Cancer Med. 2023 Apr;12(8):9085-9096. doi: 10.1002/cam4.5630. Epub 2023 Apr 6. Cancer Med. 2023. PMID: 37021846 Free PMC article.
References
-
- Greenlee RT, Murray T, Bolden S, et al. Cancer statistics 2000. CA Cancer J Clin. 2000;50:7–33. - PubMed
-
- Osgood E. The survival time of patients with plasmacytic myeloma. Cancer Chemother Rep. 1960;9:1–10. - PubMed
-
- Bergsagel DE, Sprague CC, Austin C, et al. Evaluation of new therapeutic agents in the treatment of multiple myeloma: IV. L-phenylalanine mustard (NSC-8806) Cancer Chemother Rep. 1962;21:87–99. - PubMed
-
- Alexanian R, Haut A, Khan A, et al. Treatment for multiple myeloma: Combination therapy with different melphalan dose regimens. JAMA. 1969;208:1680–1685. - PubMed
-
- Myeloma Trialists' Collaborative Group. Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: An overview of 6633 patients from 27 randomized trials. J Clin Oncol. 1998;16:3832–3842. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical